The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy
- 299 Downloads
The use of immunosuppressive medications during pregnancy in patients with Crohn's disease is controversial. However, most clinicians would agree that both the unborn baby and the mother will do better if the mother's inflammatory bowel disease (IBD) can be controlled. Studies have shown that patients with active Crohn's disease are more likely to experience preterm labor and have babies that are small for gestational age . Currently, the most potent agent approved for Crohn's disease is infliximab. This is a chimeric anti–tumor necrosis factor-alpha (TNF-α) antibody. Recently, adalimumab (Humira), a fully humanized anti–TNF-α antibody, was approved for the treatment of rheumatoid arthritis (RA) [2, 3, 4, 5]. Preliminary studies have demonstrated efficacy in patients with Crohn's disease, including those who have had a reaction to or lost their response to infliximab because of the development of antibodies to the murine component of this agent [6, 7]. The safety of adalimumab in...
KeywordsInflammatory Bowel Disease Infliximab Adalimumab Budesonide Weekly Injection
- 2.Rau R (2002) Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(suppl 2):ii70–73Google Scholar
- 5.Weisman MH, Moreland LW, Furst DE, et al. (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700–1721PubMedCrossRefGoogle Scholar
- 11.Hanauer S, Lukas M, MacIntosh D, Rutgeerts P, Sandborn WJ, Pollack P (2004) A randomized, double-blind, placebo-controlled trial of the human anti-TNF- alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 27:A332CrossRefGoogle Scholar
- 12.Sandborn WJ, Hanauer S, Lukas M, et al. (2005) Induction and maintenance of clinical response in subjects with Crohn's disease treated during a 6-month open-label period with fully humanized anti-TNF alpha monoclonal antibody adalimumab. Gastroenterology 128:A-111Google Scholar